Multidrug resistant AmpC β-lactamase producing Escherichia coli isolated from a paediatric hospital

Abstract

Objective: The objective of the study was to observe the antimicrobial resistance of AmpC β-lactamase producing E. coli.

Methods: Six hundred and seventy E. coli were isolated from 20,257 various pathological samples collected from The Children’s Hospital and Institute of Child Health, Lahore, Pakistan. The isolates showed resistance to ceftazidime which were further examined for AmpC β-lactamase activity by Disc Potentiation method.

Results: There were 670 isolates of E. coli out of which 85 (12.6%) were AmpC β-lactamase producers. Risk factors like intravenous line (76.5%), endotracheal tube (22.4%), surgery (12.9%) and urinary catheters (7.1%) were found to be associated with infection caused by AmpC β-lactamase producing E. coli. Antimicrobial resistance pattern revealed that AmpC producing E. coli were highly resistant to co-amoxiclav, ceftazidime, cefotaxime, cefuroxime, cefixime, ceftriaxone and cefoxitin (100% each). Least resistance was observed against sulbactam-cefoperazone (14.1%), cefepime (7.1%), piperacillin-tazobactam (5.9%) and none of the isolates were resistant to imipenem and meropenem.

Conclusion: The minimum use of invasive devices and strict antibiotic policies can reduce the spread of AmpC β-lactamase producing E. coli.

doi: http://dx.doi.org/10.12669/pjms.301.4045

How to cite this:Jameel NA, Ejaz H, Zafar A, Amin H. Multidrug resistant AmpC β-lactamase producing Escherichia coli isolated from a paediatric hospital. Pak J Med Sci 2014;30(1):181-184.   doi: http://dx.doi.org/10.12669/pjms.301.4045

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.